deaths (OS)progression or deaths (PFS)RFS/DFS

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 certainty unassessable-6% certainty unassessable-14%-